Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Safety and outcome of prophylactic high-dose donor CD45RO+ memory T-cells after allo-HSCT

Mercedes Gasior Kabat • 31 Aug 2020
EBMT 2020
General

Mercedes Gasior Kabat, MD, Hospital Universitario La Paz, Madrid, Spain, discusses prophylactic high-dose donor CD45RO+ memory T-cell infusion after allogeneic hemopoietic stem cell transplantation (allo-HSCT), focusing on safety and outcomes. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Mercedes Gasior Kabat

2:41
T-cell depletion targeting CD45RA in HLA-mismatched HSCT
Mercedes Gasior Kabat • 22 Jun 2021
4:22
Molecular profile impacts platelet function and thrombin generation in essential thrombocythemia
Mercedes Gasior Kabat • 22 Jun 2021
3:13
Donor NK cell infusion to prevent HHV6 reactivation in pediatric patients
Mercedes Gasior Kabat • 1 Sep 2020

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals